Fig. 1 · Structure

Documents & Downloads

Dabigatran (BIBR 953)

Cat. No. A10138 CAS 211914-51-1

Thrombin inhibitor

BIBR 953 (Dabigatran, Pradaxa) is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable pharmacodynamic response.

In Stock

Publications for Dabigatran

1 publication citing this product

  1. Tanaka M, .et al. , J Pharmacol Sci, 2016, Jul;131(3):162-71 PMID: 27426918

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Dabigatran inhibited thrombin-mediated PAR1 cleavage in PAR1-expressing HeLa cells. The measured EC50 depended on thrombin concentration, and inhibition at 100 nM dabigatran weakened over a 30–60-minute exposure. These cell-based results characterize inhibition of thrombin-driven receptor cleavage. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Thrombin (Cell-free assay) 9.3 nM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 25.3 μM Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 4.7 μM Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 8.1 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]

Dabigatran (BIBR 953) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Dabigatran (BIBR 953) from 3 published references. In vitro models include HeLa cells expressing N-terminal FLAG-tagged PAR1; HEK293-Flp-In cells stably expressing human MATE1, MATE2-K or OCT2. In vivo models include wild-type mice, laser-induced cremaster arteriolar injury.

Dabigatran (BIBR 953) In Vitro Studies

In a HEK293 transporter panel, dabigatran inhibited ASP+ uptake with IC50 values of 8.1 μM for MATE1, 25.3 μM for MATE2-K and 4.7 μM for OCT2. These cellular off-target measurements should be distinguished from thrombin potency. [2]

Inhibition of thrombin-induced PAR1 cleavage

Cell-based study · HeLa cells expressing N-terminal FLAG-tagged PAR1 [1]

Dabigatran inhibited thrombin-induced PAR1 cleavage. Potency depended on thrombin concentration; at 100 nM dabigatran, cleavage became more evident after 30–60 minutes, whereas inhibition persisted with 300 nM under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PAR1 cleavage induced by 1 nM thrombin after 5 minutesEC50 2.68 ± 0.47 nM[1]
Inhibition of PAR1 cleavage induced by 10 nM thrombin after 5 minutesEC50 17.7 ± 3.17 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 1B: 10^-10–10^-6 M dabigatran; Figure 1C: 100 or 300 nM dabigatran
Exposure duration
Thrombin preincubated with dabigatran or DMSO for 30 minutes; cell exposure 5 minutes for concentration response, up to 60 minutes for time course
Method
Thrombin–dabigatran mixtures applied to cells at 37°C; residual cell-surface N-terminal FLAG detected by ELISA
Vehicle
DMSO; final percentage not specified in the inspected assay description
Co-treatment
Challenge with 1 or 10 nM thrombin; no-thrombin and thrombin/DMSO controls
Reported limits
EC50 error definition and final DMSO percentage not specified; no recommended working concentration inferred.
Methods and source locations

Compound reported in the paper: Dabigatran; Compound label in the paper: dabigatran

Reported research result for dabigatran, not validation of an Adooq batch.

Results first two paragraphs; Figure 1B–C and caption; Methods PAR1 Cleavage, Reagents

Inhibition of PAR1 cleavage induced by 1 nM thrombin after 5 minutes: Cell-surface FLAG ELISA; Figure 1 representative of three independent experiments. Definition of ± for these EC50 values not specified in the inspected text. — Results paragraph 1; Figure 1B inset and caption

Inhibition of PAR1 cleavage induced by 10 nM thrombin after 5 minutes: Cell-surface FLAG ELISA; Figure 1 representative of three independent experiments. Definition of ± for these EC50 values not specified in the inspected text. — Results paragraph 1; Figure 1B inset and caption

Inhibition of organic cation transporter probe uptake

Cell-based study · HEK293-Flp-In cells stably expressing human MATE1, MATE2-K or OCT2 [2]

Dabigatran inhibited ASP+ uptake through all three transporters in a concentration-response validation panel. These are probe-dependent off-target assay results, not thrombin inhibition constants or proof of a clinical drug interaction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MATE1-mediated ASP+ uptake inhibitionIC50 8.1 μM (95% CI 5.7–11.5 μM)[2]
MATE2-K-mediated ASP+ uptake inhibitionIC50 25.3 μM (95% CI 12.0–53.1 μM)[2]
OCT2-mediated ASP+ uptake inhibitionIC50 4.7 μM (95% CI 2.8–8.0 μM)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Various inhibitor concentrations within the reported general assay range of 0–500 μM; exact dabigatran dilution series not enumerated
Exposure duration
ASP+ uptake: 1.5 minutes for MATE transporters; 3 minutes for OCT2
Method
Simultaneous exposure to dabigatran and 2 μM ASP+ in HBSS, pH 7.4; cellular fluorescence measured after washing
Vehicle
2% DMSO, held constant in all samples
Co-treatment
ASP+ probe; cimetidine used to define nonspecific MATE transport in the assay framework
Reported limits
Exact dabigatran concentration series, salt/solvate and compound-specific supplier assignment not stated in the inspected text.
Methods and source locations

Compound reported in the paper: Dabigatran; Compound label in the paper: dabigatran

Reported research result for dabigatran, not validation of an Adooq batch.

Table 3 dabigatran row; Methods Experimental IC50 Determination, Reagents and Cell Culture

MATE1-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination

MATE2-K-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination

OCT2-mediated ASP+ uptake inhibition: Fluorescence uptake assay; ASP+ 2 μM; uptake measured in triplicate at each inhibitor concentration. Parentheses are 95% confidence intervals. — Table 3 dabigatran row and column headings; Experimental IC50 Determination

Dabigatran (BIBR 953) In Vivo Studies

In wild-type mice, dabigatran pretreatment at 0.3 mg/kg nearly abolished platelet accumulation after laser-induced cremaster arteriolar injury compared with vehicle. The experiment measured an acute antithrombotic response and does not establish pharmacokinetics or bleeding safety. [3]

Dabigatran suppresses platelet accumulation after vascular injury

Animal study · Wild-type mice, laser-induced cremaster arteriolar injury [3]

Pretreatment with dabigatran nearly abolished platelet thrombus formation relative to vehicle in the reported intravital imaging experiment. This is an acute thrombosis endpoint; pharmacokinetics and bleeding risk were not established by this experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Platelet accumulation after arteriolar injuryMedian integrated fluorescence intensity Nearly abolished relative to vehicle; 30 thrombi in 3–4 mice per group[3]

Conditions shared by the study groups

Route
Infusion; anatomical route not specified in the inspected main text
Frequency
Pretreatment before injury; repeat schedule not specified
Treatment course
Acute experiment; Figure 7F observation 0–240 seconds
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dabigatran versus vehicle
0.3 mg/kg body weight
Vehicle controlPlatelet thrombus formation nearly abolished; median fluorescence time course from 30 thrombi in 3–4 mice per group[3]
Dabigatran versus vehicle
Model: Wild-type mice with laser-induced cremaster arteriolar injury
Reported limits: Vehicle composition, exact pretreatment interval, compound source/form detail and anatomical infusion route not retrieved; SI not available in retained main HTML links.
Methods and source locations

Compound reported in the paper: Dabigatran; Compound label in the paper: dabigatran

Reported research result for dabigatran, not validation of an Adooq batch.

Methods Fluorescence intravital microscopy; Results paragraph preceding Figure 7; Figure 7F and caption

Platelet accumulation after arteriolar injury: Fluorescence intravital microscopy; Figure 7F displays a 0–240-second time course. No percentage reduction or significance value inferred. — Figure 7F and caption; Results preceding Figure 7

Dabigatran versus vehicle · Methods Fluorescence intravital microscopy; Figure 7F and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 211914-51-1
Applications Thrombin inhibitor
Formula C25H25N7O3
Molecular Weight 471.5
Synonyms BIBR 953; Pradaxa
SMILES
CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO <1 mg/mL
Water 29 mg/mL (61.5 mM)
Ethanol 0.01 mg/mL (0.02 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
31 mg/mL
Vehicle
10% Trifluoroacetic acid water solution

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dabigatran (BIBR 953) Research References

  1. [1] Chen B, Soto AG, Coronel LJ, et al. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Molecular pharmacology (2015). PMID: 25934730 DOI: 10.1124/mol.114.096446 Source material
  2. [2] Wittwer MB, Zur AA, Khuri N, et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. Journal of medicinal chemistry (2013). PMID: 23241029 DOI: 10.1021/jm301302s Source material
  3. [3] Estevez B, Kim K, Delaney MK, et al. Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood (2016). PMID: 26585954 DOI: 10.1182/blood-2015-04-638387 Source material

Publications

1 publication citing this product

  1. Tanaka M, .et al. , J Pharmacol Sci, 2016, Jul;131(3):162-71 PMID: 27426918

Added to your cart

View Cart Checkout
Loading...